Clinical Trial
Study Details
Parents and child's doctor may plan to use or not to use hydroxyurea.
Sickle cell anemia (SCA) is an inherited blood disorder that can cause organ damage. The BABY HUG study is evaluating the use of the medication hydroxyurea at preventing organ damage in children with SCA. The purpose of this follow-up study is to evaluate the long-term effects of hydroxyurea in children who have participated in the BABY HUG study.
Study Overview
SCA is an inherited blood disorder in which the body makes sickle-shaped red blood cells that contain abnormal hemoglobin. The sickled cells block blood flow in the vessels that lead to limbs and organs. This can cause pain, serious infections, and organ damage. The BABY HUG study (NCT00006400) is examining whether the medication hydroxyurea can prevent organ damage, especially in the spleen and kidneys, in children with SCA. This study is a follow-up study to the BABY HUG study and will enroll children who have participated in the BABY HUG study. The purpose of this study is to examine the long-term effects of using hydroxyurea as a treatment for SCA, including both the risks and benefits. Study researchers will also investigate the optimal age to begin treatment with hydroxyurea in children with SCA.
This study will enroll children between 2 and 7 years old who participated in the BABY HUG study. Hydroxyurea will not be provided to participants as part of this study, but participants may receive the medication from their own doctors. Parents of participants can choose for their child to participate in this study in one of two ways-by enrolling in either a passive follow-up group or an active follow-up group. For participants in the passive follow-up group, study researchers will review participants' medical records every 6 months, in addition to reviewing brain ultrasound tests and computed tomography (CT) or magnetic resonance imaging (MRI) scans, if completed. Participants will have a blood and urine collection at baseline and Year 4 (or at the end of the study, whichever comes first). Participants in the active follow-up group will take part in the same study procedures as participants in the passive follow-up group. In addition, at Year 2, participants in this group will undergo an additional blood and urine collection, a scanning procedure to obtain images of the liver and spleen, a kidney test, neuropsychological testing, and an ultrasound imaging test to evaluate liver and spleen size.
Contacts and Locations
University of Alabama at Birmingham
Birmingham, Alabama 35233
United States
Children's National Medical Center
Washington D.C., District of Columbia 20010
United States
Howard University College of Medicine
Washington D.C., District of Columbia 20060
United States
University of Miami School of Medicine
Miami, Florida 33136
United States
Emory University School of Medicine
Atlanta, Georgia 30342
United States
Johns Hopkins University School of Medicine
Baltimore, Maryland 21205
United States
Children's Hospital of Michigan/Wayne State University
Detroit, Michigan 48201
United States
University of Mississippi Medical Center
Jackson, Mississippi 39216
United States
Downstate Medical Center
Brooklyn, New York 11203
United States
Duke University Medical Center
Durham, North Carolina 27710
United States
Drexel University
Philadelphia, Pennsylvania 19134
United States
Medical University of South Carolina
Charleston, South Carolina 29425
United States
St. Jude Children's Research Hospital
Memphis, Tennessee 38105
United States
University of Texas Southwestern Medical Center at Dallas
Dallas, Texas 75390
United States